Small Molecules Targeting 5-meCpG Binding Domain Proteins (MBDs) for Cancer Prevention and Treatment, and for Other Clinical Uses

JHU scientists have discovered new small molecules inhibitors of the transcriptional repression pathway mediated by the 5m-CpG-binding family domain proteins (MBD), MBD2 and MeCP2. Both MBD2 and MeCP2 have been found to play critical roles in both the epigenetic silencing of gene in human cancer cells and in the development of intestinal adenomas in APC min/+ mice. The inhibitors describes in this invention can be used to reverse the epigenetic silencing of critical genes that accompanies cancer development Description (Set) Proposed Use (Set) The inhibitors can be developed for the treatment of multiple cancers and sickle cell anemia.

Inventor(s): Nelson, William G.

Type of Offer: Licensing



« More Medical Patents

---